Project Grant R01CA293735
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$619K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This $687,995 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a randomized clinical trial conducted by Yale University to investigate the efficacy of varenicline for cessation of e-cigarette use in adults. The study aims to compare quit rates between varenicline and placebo treatments, assess predictors and moderators of outcomes, and explore changes in cancer-related biomarkers following e-cigarette...
This $3,257,011 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will evaluate a tobacco harm reduction strategy among clients enrolled in substance use disorder (SUD) treatment. The study proposes a hybrid type 1 effectiveness-implementation randomized controlled trial to compare the impact of switching to electronic nicotine delivery systems (ENDS) versus using nicotine replacement therapy (NRT)...
The National Cancer Institute (NCI) awarded a $625,201 Project Grant under the federal Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Oklahoma Health Sciences Center to conduct a randomized factorial trial. The study will evaluate the combined impact of varenicline medication with nicotine lozenges, as well as the influence of a smartphone-based medication adherence intervention, on smoking cessation outcomes among 496 adult daily smokers. The primary...
This Project Grant award for $1,951,307 from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a comprehensive study on the dual use of combustible and electronic cigarettes. The study aims to describe and compare the use patterns and trajectories of dual users versus exclusive users of combustible or electronic cigarettes over a 1-year period. Key research activities include: Collecting detailed daily diaries, nightly...
This federal Project Grant award, valued at $257,415, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award aims to create a scalable, AI-enhanced smartphone application intervention to facilitate e-cigarette cessation among adolescents. The project will involve pilot testing the intervention using a quasi-randomized controlled study design to evaluate its usability, user engagement, and effectiveness in reducing...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $310,319 to the University of Louisville to conduct formative research on developing a motivation-based typology of adolescent e-cigarette users. The goal is to inform the development of tailored cognitive-behavioral cessation interventions for this population. The research will involve surveying 1,200 high school students who have used e-cigarettes in the past...
The National Cancer Institute (NCI) awarded a $707,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Kaiser Foundation Hospitals to evaluate a novel mobile health (mHealth) smoking cessation intervention for people who are ambivalent about quitting smoking. The 5-year project, titled "Evaluation of a Novel mHealth Intervention for People Who Are Ambivalent About Quitting Smoking: A Randomized Controlled Trial," will develop and test the...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $1,698,536 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a double-blind, parallel group, intent-to-treat trial evaluating the effectiveness of the QuitVaping digital and behavioral intervention compared to enhanced usual care for promoting nicotine vaping cessation and preventing escalation of...
The National Cancer Institute (NCI) awarded a $515,632 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Regents of the University of Minnesota. The 3-year grant, starting on May 2, 2025, aims to ensure the U.S. is prepared to maximize smoking cessation during and following the implementation of proposed cigarette product standards by the FDA. The project will: 1) Estimate, for each U.S. state, the number and fold increase of people who smoke (PWS) who...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $399,891 to Sensewhy, Inc. to develop and evaluate a system for remote monitoring of smoking behavior and intervention among cancer survivors. The key products or services to be delivered include: Feasibility evaluation of the "Smokemon" wearable device to detect and measure smoking topography (physical characteristics of smoking behavior) in...